Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

105 results about "Head trauma" patented technology

Head trauma is an injury to the head when, for example, you fall and hit your head or something hits you on the head. Sometimes you may be hit hard enough that you have a concussion, which is an injury to the brain caused by a blow to the head.

Method for assessing brain function and portable automatic brain function assessment apparatus

A method and apparatus for performing rapid brain assessment may provide emergency triage to head trauma patients by analyzing a combination of spontaneous and evoked brain potentials. The spontaneous and evoked potentials are analyzed, and the results classified, to present a real-time assessment of a patient's brain, diagnosing any potential abnormalities therein.
Owner:BS HLDG +2

Intravascular methods and apparatus for isolation and selective cooling of the cerebral vasculature during surgical procedures

Patients having diminished circulation in the cerebral vasculature as a result of stroke or from other causes such as cardiac arrest, shock or head trauma, or aneurysm surgery or aortic surgery, are treated by flowing an oxygenated medium through an arterial access site into the cerebral vasculature and collecting the medium through an access site in the venous site of the cerebral vasculature. Usually, the cold oxygenated medium will comprise autologous blood, and the blood will be recirculated for a time sufficient to permit treatment of the underlying cause of diminished circulation. In addition to oxygenation, the recirculating blood will also be cooled to hypothermically treat and preserve brain tissue. Isolation and cooling of cerebral vasculature in patients undergoing aortic and other procedures is achieved by internally occluding at least the right common carotid artery above the aortic arch. Blood or other oxygenated medium is perfused through the occluded common carotid artery(ies) and into the arterial cerebral vasculature. Usually, oxygen depleted blood or other medium leaving the cerebral vasculature is collected, oxygenated, and cooled in an extracorporeal circuit so that it may be returned to the patient. Occlusion of the carotid artery(ies) is preferably accomplished using expansible occluders, such as balloon-tipped cannula, catheters, or similar access devices. Access to the occlusion site(s) may be open surgical, percutaneous, or intravascular.
Owner:BARBUT DENISE +3

Substituted diarylalkyl amides as calcium channel antagonists

The present invention provides compounds that block calcium channels and have the Formula I:The present invention also provides pharmaceutical compositions containing the compounds of Formula I and methods of using them to treat stroke, cerebral ischemia, head trauma, and epilepsy.
Owner:WARNER-LAMBERT CO

Low level light therapy for enhancement of neurologic function

Therapeutic methods for enhancing neurologic function such as may be desired in individuals having motor and / or cognitive impairment, including that resulting from Alzheimer's disease, dementia, head trauma, mental disease such as depression, stroke and neurodegeneration, as well as in healthy individuals are described, the methods including delivering a cognitive enhancing effective amount of light energy having a wavelength in the visible to near-infrared wavelength range to a target area of the brain. The neurologic function enhancing effective amount of light energy, in accordance with a preferred embodiment, is a predetermined power density (mW / cm2) at the level of the brain tissue being treated, and is delivered by determining a surface power density of the light energy that is sufficient to deliver the predetermined power density of light energy to the target brain tissue. In one embodiment, progenitor cells are treated using light energy and implanted into the central nervous system of a patient.
Owner:PHOTOTHERA IP HLDG

Method for assessing brain function and portable automatic brain function assessment apparatus

A method and apparatus for performing rapid brain assessment may provide emergency triage to head trauma patients by analyzing a combination of spontaneous and evoked brain potentials. The spontaneous and evoked potentials are analyzed, and the results classified, to present a real-time assessment of a patient's brain, diagnosing any potential abnormalities therein.
Owner:BS HLDG +2

Brain assessment monitor

A non-invasive brain assessment monitor is disclosed. An embodiment of the monitor includes a head-mounted brain sensor which passively senses acoustic signals generated from pulsing blood flow through a patient's brain. A reference sensor may be mounted at another location on the patient's body to sense an arterial pulse, and the signals from the brain sensor and reference sensor may be compared. Another embodiment includes transmitters which generate acoustic signals in the brain which are also detected by the brain sensor. The brain assessment monitor may be used to detect conditions such as head trauma, stroke and hemorrhage.
Owner:ACTIVE SIGNAL TECH

Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease

InactiveUS20120263764A1Organic active ingredientsBiocideHuntingtons choreaTolerogenic therapy
Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke / cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and / or modulating the function and / or activity of effector T-cells, and / or for cell-based tolerogenic therapy (e.g., by modulating development and / or function and / or activity of TREG cells and / or dendritic cells (DCs) and / or TH17 cells (e.g., RORĪ³t+ TH17 cells). In certain aspects such methods comprise ex vivo exposure of T-cells and / or APC (e.g., dendridic cells) to at least one electrokinetically-altered fluid as disclosed herein. Combination therapies are additionally provided.
Owner:REVALESIO CORP

Substituted amides

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP

Compositions and methods for the treatment of disorders of the central and peripheral nervous systems

InactiveUS20060035914A1Reducing neurodegenerative effectReduced activitySalicyclic acid active ingredientsBiocideDiseaseNervous system
The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neuropsychiatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and / or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Electrolyte cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed.
Owner:NEUROTHERAPEUTICS PHARMA

Head Trauma Bandage Cap and Method

ActiveUS20120296252A1Control bleedingMinimize movementHead bandagesNeck bandagesCervical spine immobilizationCold packs
An emergency head trauma bandage cap with a detachable strap system and method of use, which, when applied to the head, delivers minimal pressure to control bleeding, doesn't compromise cervical spine immobilization, allows for fast and effective application of cold packs to control intracranial / internal swelling or hot packs to prevent hypothermia in non-trauma situations, doesn't come apart during treatment and transport, and doesn't require a caregiver to re-wrap the dressing.
Owner:EQUALIZER TECHNOLOGY LLC

Cold Plasma Treatment Devices and Associated Methods

ActiveUS20130072859A1Utility in controlIncrease blood flowElectrotherapyElectric discharge tubesClosed head injuryEngineering
A cold plasma helmet application device for delivery of cold plasma benefits to the head of a patient. An appropriate gas is introduced into a helmet receptacle within a containment dome of the helmet. The gas is energized by one or more dielectric barrier devices that receive energy from a pulsed source. The dielectric barrier devices can be configured to match the treatment area. Such a device and method can be used to treat large surface areas treatment sites associated with the head, head trauma, brain cancer, the control of brain swelling with closed head injury or infection, as well as treating male pattern baldness.
Owner:COLD PLASMA MEDICAL TECH

Substituted pyrimidines

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP

Bicyclic amides

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP

Head trauma cap bandage and method

InactiveUS20090299259A1Fast and easy to applyAbsorb and control bleedingHead bandagesNeck bandagesCervical spine immobilizationEmergency medicine
An emergency head trauma cap bandage and method of use, which, when applied, applies compression pressure to stop bleeding, doesn't compromise cervical spine immobilization, doesn't come apart during treatment and transport, and doesn't require a caregiver to re-wrap the dressing.
Owner:CUMMING MICHELLE +1

Therapeutic uses for mesenchymal stromal cells

InactiveUS20040208858A1BiocideGenetic material ingredientsMetachromatic leukodystrophyTay-Sachs disease
Human mesenchymal stromal cells can be induced to differentiate into oligodendrocytes and neurons, respectively. For these cell types, therefore, MSCs can be a therapeutic source, either in vitro or in vivo, in the context of treating pathologies of the central nervous system which are characterized by neuron loss, such as Parkinson's disease, Alzheimer's disease and stroke, as well as head trauma, or by dysfunction in ganglioside storage or demyelinization, such as Tay-Sachs disease, G1 gangliosidosis, metachromatic leukodystrophy, and multiple sclerosis.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA

Non-sedating barbituric acid derivatives

The present invention relates to novel non-sedating barbituric acid derivatives, pharmaceutical compositions containing them and methods of neuroprotection in cases of cerebral ischemia, head trauma and other acute neurologic injuries, and prevention of resulting neuronal damage. The invention also relates to the use of non-sedating barbituric acid derivatives given in a manner and dosage effective to produce blood levels and brain levels of these drugs and / or their active metabolites sufficient to provide a therapeutic effect.
Owner:TARO PHARMA INDS

Composition for treating autonomic nerve disorder, preparation and uses thereof

The invention discloses a composition taking cycloartenyl ferulate and 24-methylene cycloartenyl ferulate as active ingredients, a preparation of the composition used as a medicine, and an application of the preparation. The total content of the cycloartenyl ferulate and the 24-methylene cycloartenyl ferulate is over 90 percent of the total active ingredients by weight percentage. As the medicine, the composition can be injection and frozen-dried powder injection and also can be an oral solid preparation, a medicine composition used for treating autonomic imbalance, climacteric syndrome, primary dysmenorrheal and premenstrual tension, periodic psychosis, vascular headache, head trauma syndrome, gastrointestinal imbalance and hyperlipemia, etc.
Owner:BEIJING CENTURY BIOCOM PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products